The humanized anti-TNF-alpha antibody, CDP571, is well tolerated and able to cause a dose-dependent reduction in circulating TNF-alpha concentrations in patients with septic shock. Further studies are needed to determine the efficacy of this antibody to improve the survival rates of critically ill patients with severe sepsis.
Charles J. Fisher, Steven M. Opal, Jean-François Dhainaut, Sue Stephens, Janice L. Zimmerman, Peter Nightingale, S. Harris, Roland M.H. Schein, Edward A. Panacek, Jean Louis Vincent, Garrett E. Foulke, Edward Warren, CHRIS GARRARD, Gilbert Park, Mark Bodmer, Jonathan Cohen, CEES VAN DER LINDEN, Alan S. Cross, Jerald Sadoff
Discussion(0)
No comments yet. Be the first to comment.